biotech

$ENVB surges 106% after Trump orders federal acceleration of psychedelic treatment approvals and commits $50M to ibogaine research, though stock remains deeply depressed technically.

Dianthus Therapeutics CFO Ryan Savitz sold 8,224 shares for $739,000 on April 9, 2026, reducing direct holdings to zero while retaining substantial options.

Kailera Therapeutics raised $625M in largest biotech IPO since 2021, entering competitive obesity market with oral GLP-1 candidate showing 12.1% weight loss.

$VKING develops competing obesity drugs against $LLY and $NVO, with oral candidate entering phase 3 trials in Q3 2026 amid projected $100B market expansion.

Eli Lilly acquires Centessa Pharmaceuticals for $6.3B, gaining neuroscience assets. Stock rises on strong financial footing from weight-loss drug success.

Biogen's three-decade outperformance is challenged by biosimilar competition and weak growth, though new Alzheimer's and rare disease drugs offer hope. Success requires flawless execution.

Praxis Precision shares surge 7.15% after FDA accepts essential tremor drug application with January 2027 decision target and positive Phase 3 results.

MD&M South 2026 announces partnerships with industry organizations to enhance its Charlotte medical device manufacturing event through networking, sustainability, and innovation initiatives.

CRISPR Therapeutics holds $2B cash reserves funding gene-therapy expansion, while Casgevy sales accelerate to $116M in 2025.

Nuvation Bio's Chief Regulatory Officer sold 200,000 shares for $904K but retained 53,000 shares and 700,000 options, suggesting routine profit-taking rather than lost confidence.

Vir Biotechnology CEO Marianne De Backer sold 72,559 shares worth $664,350, representing 6.76% of holdings. Sale aligns with historical patterns amid company's positive momentum.

Beam Therapeutics CEO John Evans sold 30,078 shares for $739K via pre-planned tax obligation. Strong 2025 revenue growth and $1.2B cash reserves indicate company health.

Iovance's Amtagvi cancer therapy targets $1B+ revenue by 2030 amid strong early growth, but faces manufacturing cost and regulatory risks.

Three small-cap stocks with depressed valuations—Innoviva, Wendy's, and Nabors Industries—offer potential upside despite sector headwinds, analyst projections show.

Biotech hedge fund BVF Partners sold $63M in MoonLake shares, trimming its stake 78% while retaining 15.9M shares, amid broader sector volatility.

Gilead acquires Tubulis for $3.15 billion including milestones, adding HER2-targeting ovarian cancer candidate to oncology pipeline—second major deal in months.

Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9B in all-cash deal, paying $53/share—a 34% premium driven by Soleno's FDA-approved Vykat XR for Prader-Willi Syndrome.

Dianthus CFO Ryan Savitz sold $9.5M in stock, liquidating all direct holdings while retaining options, following the company's exceptional 402% year-over-year rally.

Neurocrine acquires Soleno for $2.9B to gain Vykat XR, a rare disease blockbuster generating $190M in 2025 revenue.

Liquidia's chairman sold $2.5M in stock but retained 2M+ shares. The 3% stake reduction reflects liquidity management, not lost confidence, as the company surges 159.5% and achieves profitability.